Stocks are pricey—but there are values to be had. Learn more about our panelists’ picks in this week’s Roundtable installment.

In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor ...

DDS benefits from its efforts to capture growth opportunities in brick-and-mortar stores and the e-commerce business.

The health-care sector has been rebounding recently following a sharp selloff in recent weeks amid hopes that controversy would die down. The health-care industry group was among the leading S&P 500 ...

The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...

Health-care companies slid after a profit warning from Eli Lilly. Shares of the obesity-drug maker tumbled after it slashed its projection for fourth-quarter revenue as the market for drugs that ...

Eli Lilly's LLY short percent of float has risen 5.88% since its last report. The company recently reported that it has 6.10 million shares sold short, which is 0.72% of all regular shares that are ...

Eli Lilly and Company will establish a new global capability centre in Hyderabad and recruit more than 1,000 highly skilled team members to strengthen its digital strategy and service delivery.

customer support, R&D and other business functions. According to a recent report from EY, there are roughly 1,580 GCCs in India employing more than 1.6 million people. The Lilly Capability Centre ...